Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study

BMC Psychiatry

Richard I. G. Holt¹  Robert C. Peveler²  Carolyn Asher³  Peter Phiri³  Hermione C. Price³  Clare A. Whicher⁴  Katharine Barnard-Kelly⁵  Shanaya Rathod⁶ 

[1] Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Tremona Road, SO16 6YD, Southampton, UK;Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK;Southern Health NHS Foundation Trust, Research & Development Department Tom Rudd Unit, Moorgreen Hospital, Botley Rd, SO30 3JB, West End, Southampton, UK;Southern Health NHS Foundation Trust, Research & Development Department Tom Rudd Unit, Moorgreen Hospital, Botley Rd, SO30 3JB, West End, Southampton, UK;Academic Department of Psychiatry, College Keep, Terminus Terrace, SO14 3DT, Southampton, UK;Southern Health NHS Foundation Trust, Research & Development Department Tom Rudd Unit, Moorgreen Hospital, Botley Rd, SO30 3JB, West End, Southampton, UK;BHR Limited, Fareham, Hampshire, UK;Southern Health NHS Foundation Trust, Research & Development Department Tom Rudd Unit, Moorgreen Hospital, Botley Rd, SO30 3JB, West End, Southampton, UK;Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK;

关键词: Liraglutide;    Obesity;    Overweight;    Severe mental illness;    Schizophrenia;    Psychosis;   

DOI  :  10.1186/s12888-021-03666-5

来源: Springer

【 摘 要 】

BackgroundPeople with severe mental illness are two to three times more likely to be overweight or have obesity than the general population and this is associated with significant morbidity and premature mortality. Liraglutide 3 mg is a once daily injectable GLP-1 receptor agonist that is licensed for the treatment of obesity in the general population and has the potential to be used in people with severe mental illness.AimsTo record the expectations and experiences of people with schizophrenia, schizoaffective disorders or first episode psychosis taking daily liraglutide 3 mg injections in a clinical trial for the treatment of obesity.To seek the views of healthcare professionals about the feasibility of delivering the intervention in routine care.MethodsQualitative interviews were undertaken with a purposive sub-sample of people with schizophrenia, schizoaffective disorders or first episode psychosis with overweight or obesity who were treated with a daily injection of liraglutide 3 mg in a double-blinded, randomised controlled pilot study evaluating the use of liraglutide for the treatment of obesity. Interviews were also conducted with healthcare professionals.ResultsSeventeen patient participants were interviewed. Sixteen took part in the baseline interview, eight completed both baseline and follow-up interviews, and one took part in follow-up interview only. Mean interview duration was thirteen minutes (range 5-37 min). Despite reservations by some participants about the injections before the study, most of those who completed the trial reported no challenges in the timing of or administering the injections. Key themes included despondency regarding prior medication associated weight gain, quality of life impact of weight loss, practical aspects of participation including materials received and clinic attendance. Healthcare professionals reported challenges with recruitment, however, overall it was a positive experience for them and for participants.ConclusionLiraglutide appears to be an acceptable therapy for obesity in this population with limited side effects. The quality of life benefits realised by several intervention participants reinforce the biomedical benefits of achieved weight loss.

【 授权许可】

CC BY